Form 8-K - Current report:
SEC Accession No. 0001193125-23-060173
Filing Date
2023-03-03
Accepted
2023-03-03 17:08:07
Documents
12
Period of Report
2023-03-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d444684d8k.htm   iXBRL 8-K 25202
  Complete submission text file 0001193125-23-060173.txt   150125

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acrv-20230303.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20230303_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20230303_pre.xml EX-101.PRE 11699
6 EXTRACTED XBRL INSTANCE DOCUMENT d444684d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 23705558
SIC: 2834 Pharmaceutical Preparations